Tumour surveillance: Missing peptides and MHC molecules

Immunology and Cell Biology

Volumn 76, Issue 1, 1998, Pages 20-26

  Khanna, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Antigen processing; Cytotoxic T lymphocytes; Histocompatibility leucocyte antigen; Immune escape; Immunotherapy; Peptide transporters; Tumours

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; IMMUNOSURVEILLANCE; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PROTEIN TARGETING; PROTEIN TRANSPORT; TUMOR GROWTH;

ANIMALS; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PEPTIDES;

EID: 0031925053     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.1998.00717.x     Document Type: Article

References (55)

1. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
2. Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 1994; 179: 921-30.
3. Boel P, Wildmann C, Sensi ML et al. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 1995; 2: 167- 75.
4. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr. Opin. Immunol. 1996; 8: 628-36.
5. Coulie PG, Lehmunn F, Lethe B et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl Acad. Sci. USA 1995; 92: 7976-80.
6. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance. Immunol. Today 1995; 16: 487-94.
7. Goodenow RS, Vogel JM, Linsk RL. Histocompatibility antigens on murine tumors. Science 1985; 230: 777-83.
8. Marincola FM, Shamamian P, Alexander RB et al. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J. Immunol. 1994; 153: 1225-37.
9. Rivoltini L, Barracchini KC, Viggiano V et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res. 1995; 55: 3149-57.
10. Andersson ML, Stam NJ, Klein G, Ploegh HL, Masucci MG. Aberrant expression of HLA class-I antigens in Burkitt lymphoma cells. Int. J. Cancer 1991; 47: 544-50.
11. Darrow TL, Slingluff CL Jr, Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes: Evidence for shared tumor antigens. J. Immunol. 1989; 142: 3329-35.
12. Neefjes JJ, Momburg F. Cell biology of antigen presentation. Curr. Opin. Immunol. 1993; 5: 27-34.
13. Schumacher TN, Kantesaria DV, Serreze DV, Roopenian DC, Ploegh HL. Transporters from H-2b, H-2d, H-2s, H-2k, and H-2g7 (NOD/Lt) haplotype translocate similar sets of peptides. Proc. Natl Acad. Sci. USA 1994; 91: 13 004-8.
14. Goldberg AL. Functions of the proteasome: The lysis at the end of the tunnel (comment). Science 1995; 268: 522-3.
15. Groettrup M, Soza A, Kuckelkorn U, Kloetzel PM. Peptide antigen production by the proteasome: Complexity provides efficiency. Immunol. Today 1996; 17: 429-35.
16. Spies T, Bresnahan M, Bahram S, Arnold D, Blanck G, Mellins E. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature 1990; 348: 744-7.
17. Trowsdale J, Hanson I, Mockridge I, Beck S, Townsend A, Kelly A. Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. Nature 1990; 348: 741-4.
18. Roelse J, Gromme M, Momburg F, Hammerling G, Neefjes J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J. Exp. Med. 1994; 180: 1591-7.
19. van Endert PM, Tampe R, Meyer TH, Tisch R, Bach JF, McDevitt HO. A sequential model for peptide binding and transport by the transporters associated with antigen processing. Immunity 1994; 1: 491-500.
20. Wei ML, Cresswell P. HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides. Nature 1992; 356: 443-6.
21. Henderson RA, Michel H, Sakaguchi K et al. HLA-A2.1-associated peptides from a mutant-cell line: a second pathway of antigen presentation. Science 1992; 255: 1264-6.
22. + T-cells. Nature 1993; 364: 158-61.
23. + CTL. J. Immunol. 1995; 154: 6140-56.
24. Khanna R, Burrows SR, Moss DJ, Silins SL. Peptide transporter (TAP-1/2)-independent endogenous processing of Epstein-Barr Virus (EBV) latent membrane protein 2A: Implications for CTL control of EBV-associated malignancies. J. Virol. 1996; 70: 5357-62.
25. Ortmann B, Copeman J, Lehner PJ et al. A critical role for tapasin in the assembly and function of multimeric MHC class I-TAP complexes. Science 1997; 277: 1306-9.
26. Rosenberg SA, Lotze MT, Yang JC et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer . J. Clin. Oncol. 1989; 7: 1863-74.
27. Kageshita T, Nakamura T, Yamada M, Kuriya N, Arao T, Ferrone S. Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions. Cancer Res. 1991; 51: 1726-32.
28. Rowe M, Khanna R, Jacob CA et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: Coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol. 1995; 25: 1374-84.
29. Browning MJ, Bodmer WF. MHC antigens and cancer: Implications for T-cell surveillance. Curr. Opin. Immunol. 1992; 4: 613-18.
30. White CA, Thomson SA, Cooper L et al. Constitutive transduction of peptide transporter and HLA genes restores antigen processing function and cytotoxic T cell-mediated immune recognition of human melanoma cells. Int. J. Cancer 1998; 75: (in press).
31. Khanna R, Burrows SR, Jacob CA, Rickinson AB, Moss DJ. Defective presentation of EBV CTL epitopes by Burkitt's lymphoma cells: Implications for tumour pathogenesis. Proceedings of 5th International Symposium on Epstein-Barr Virus and Associated Diseases; 1992 Sep 13-19: Annecy.
32. Khanna R, Burrows SR, Argaet V, Moss DJ. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int. Immunol. 1994; 6: 639-45.
33. Restifo NP, Esquivel F, Kawakami Y et al. Identification of human cancers deficient in antigen processing. J. Exp. Med. 1993; 177: 265-72.
34. Sanda MG, Restifo NP, Walsh JC et al. Molecular characterization of defective antigen processing in human prostate cancer (comments). J. Natl Cancer Inst. 1995; 87: 280-5.
35. Kurokohchi K, Carrington M, Mann DL et al. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 1996; 23: 1181-8.
36. Seliger B, Hohne A, Knuth A et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: Evidence for deficiencies associated with transformation and progression. Cancer Res. 1996; 56: 1756-60.
37. Cromme FV, van Bommel PF, Walboomers JM et al. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br. J. Cancer 1994; 69: 1176-81.
38. Rotem-Yehudar R, Groettrup M, Soza A, Kloetzel PM, Ehrlich R. LMP-associated proteolytic activities and TAP-dependent peptide transport for class 1 MHC molecules are suppressed in cell lines transformed by the highly oncogenic adenovirus 12. J. Exp. Med. 1996; 183: 499-514.
39. Cromme FV, Airey J, Heemels MT et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med. 1994; 179: 335-40.
40. Kaklamanis L, Leek R, Koukourakis M, Gatter KC, Harris AL. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic vs primary breast cancer. Cancer Res. 1995; 55: 5191-4.
41. Kaklamanis L, Townsend A, Doussis-Anagnostopoulou IA, Mortensen N, Harris AL, Gatter KC. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am. J. Pathol. 1994; 145: 505-9.
42. Chen PW, Wang M, Bronte V, Zhai YF, Rosenberg SA, Restifo NP. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor associated antigen. J. Immunol. 1996; 156: 224-31.
43. Rose JK, Doms RW. Regulation of protein export from the endoplasmic reticulum. Anna. Rev. Cell Biol. 1988; 4: 257-88.
44. Snyder HL, Yewdell JW, Bennink JR. Trimming of antigenic peptides in an early secretory compartment. J. Exp. Med. 1994; 180: 2389-94.
45. Zweerink HJ, Gammon MC, Utz U et al. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J. Immunol. 1993; 150: 1763-71.
46. Wolfel T, Schneider J, Zumbuschenfelde KHM. Rammensee HG, Rotzschke O, Falk K. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-a2.1. Int. J. Cancer 1994; 57: 413-18.
47. + T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int. J. Cancer 1994; 58: 69-79.
48. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl Acad. Sci. USA 1994; 91: 9461-5.
49. + EBV-specific CTL. J. Immunol. 1997; 157: 3619-25.
50. Kern DE, Klarnet JP, Jensen MC, Greenberg PD. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J. Immunol. 1986; 136: 4303-10.
51. Ostrand Rosenberg S, Roby CA, Clements VK. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J. Immunol. 1991; 147: 2419-22.
52. Maeurer MJ, Gollin SM, Martin D et al. Tumor escape from immune recognition: Lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. Clin. Invest. 1996; 98: 1633-41.
53. Seliger B, Hohne A, Jung D et al. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp. Hematol. 1997; 25: 608-14.
54. Khanna R, Cooper L, Keinzel N et al. Engagement of CD40 antigen with soluble CD40-ligand upregulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J. Immunol. 1997; (in press).
55. Irvine KR, McCabe BJ, Rosenberg SA, Restifo NP. Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL. J. Immunol. 1995; 154: 4651 7.